Clenbuterol
Type 2 Diabetes
Maastricht UniversitySmall moleculePhase 2Active
CCC
54/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 73/ 100
Competitive context
141 Active assets in the Type 2 Diabetes cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Liraglutide RenJi Hospital | Phase 4 | BBB |
Semaglutide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Exenatide Vivani Medical, Inc | Phase 4 | BBB |
Cotadutide AstraZeneca | Phase 2 | BBB |
Dapagliflozin Bhavya Bhavya, MD | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Clenbuterol is also rated in:
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease DementiaDormant
B
Indicative ·
57 / 100
View asset →glycogen storage disease due to acid maltase deficiency, late-onsetDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →